| 摘要: |
| 肝母细胞瘤(hepatoblastoma, HB)是儿童最常见的肝脏恶性肿瘤,其诊疗方式在近30年逐渐改变,从单一的手术切除治疗发展为多学科综合治疗模式。目前,各大研究中心着重关注于患儿的危险度分组及分层治疗,并在不断寻找新的潜在与预后相关的高危因素。本文从病因学、临床诊断、危险度分组标准、治疗原则及预后因素等方面综述HB的研究进展。 |
| 关键词: 肝母细胞瘤 儿童 综合疗法 |
| DOI：10.3724/SP.J.1008.2015.00315 |
| 投稿时间：2014-11-30修订日期：2015-02-10 |
| 基金项目: |
|
| Diagnosis and treatment of hepatoblastoma in children: recent progress |
| TANG Meng-jie,YUAN Xiao-jun* |
(Department of Pediatric Hematology/Oncology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China
*Corresponding author) |
| Abstract: |
| Hepatoblastoma is the most commonly-seen liver tumor in children. The past 30 years has witnessed graduall changes in the diagnosis and treatment of HB: from single operative excision to multimodality therapies. Recently many research groups have focused on the risk groups and stratified treatment, looked for novel potential prognostic risk factors. This paper reviewed the etiology, clinical diagnosis, criterion of risk groups, treatment principle, and prognosis factors of hepatoblastoma in children. |
| Key words: hepatoblastoma child combined modality therapy |
